Any day a new study shows a potential cure for cancer is a good day, and scientists in Europe may have found a breakthrough for breast cancer. The most common cancer in women, about 1 in 8 American women will develop in your life; the clinical trial may have found a way to get rid of it once and for all in the future.
Breakthrough Breast Cancer
The research presented by Professor Nigel Bundred at the European Cancer Conference in Amsterdam revealed that they had tested the effectiveness of a pair of drugs known as Herceptin (a.k.a trastuzumab) and lapatinib.
The two drugs are commonly used in the treatment of breast cancer already, but this is the first time we have combined together and used before surgery and chemotherapy. What they found was that they were able to remove some types of breast cancer in just 11 days.
funded by Cancer Research UK, which aimed to use these drugs to combat a protein called HER2 (human epidermal growth factor receptor of 2) that affects the growth and division of cancer cells. They are also more likely to return than other types of cancer.
What also makes this treatment so attractive is the fact that the need for chemotherapy and surgery is eliminated. temporary side effects such as hair loss, vomiting and fatigue are also avoided, making the treatment less impact on the body. Chemo is not entirely effective, nor is the best choice for a lot of patients, so be welcomed any alternative.
257 women were selected
with HER2 positive for the study, with half of their introduction into the drug combination cancer and half were the control group. What they found was that of drug, 11% had no remaining cancer cells within two weeks and 17% of cases had drastically reduced tumors.
Compared with the control group who received only Herceptin, which were found to have 0% without any trace of cancer cells and only 3% showed a decrease in tumor size. Clearly, the two combined drugs have an important effect on cells of breast cancer instead of being used on their own.
The current problem, however, is that licensing makes Herceptin is only available for use in conjunction with chemotherapy and not alone. The results of this study may help change that though.
Although there is still much work to be done, hopefully, this is an important step in the fight against one of the deadliest diseases in the world step. With medical advances improving every year, it is very possible that this could happen sooner than we think!